Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 8, 2010, Pages 1559-1565

  Pfaffen, Stefanie ^a   Frey, Katharina ^a   Stutz, Irène ^a   Roesli, Christoph ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Antibody; MMP 1A; MMP 2; MMP 3; Tumour targeting

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; IODINE 125; MATRIX METALLOPROTEINASE 1A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SP1; MONOCLONAL ANTIBODY SP2; MONOCLONAL ANTIBODY SP3; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; IMMUNOFLUORESCENCE; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLONING, MOLECULAR; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; MICE; MOLECULAR IMAGING; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 77956154773     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1446-9     Document Type: Article

References (10)

1. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev Immunol 6 343 357 10.1038/nri1837 1:CAS:528:DC%2BD28XjslOhu7o%3D 16622479
2. D Neri R Bicknell 2005 Tumour vascular targeting Nat Rev Cancer 5 436 446 10.1038/nrc1627 1:CAS:528:DC%2BD2MXks1Gmsrw%3D 15928674
3. CM Overall O Kleifeld 2006 Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat Rev Cancer 6 227 239 10.1038/nrc1821 1:CAS:528:DC%2BD28Xhslelt70%3D 16498445
4. S Pfaffen T Hemmerle M Weber D Neri 2010 Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3 Exp Cell Res 316 836 847 10.1016/j.yexcr.2009.11.004 1:CAS:528:DC%2BC3cXitlWjs7o%3D 19913533
5. RL Scherer JO McIntyre LM Matrisian 2008 Imaging matrix metalloproteinases in cancer Cancer Metastasis Rev 27 679 690 10.1007/s10555-008-9152-9 18465089
6. L Borsi E Balza M Bestagno P Castellani B Carnemolla A Biro, et al. 2002 Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int J Cancer 102 75 85 10.1002/ijc.10662 1:CAS:528:DC%2BD38XnvFCru7g%3D 12353237
7. A Villa E Trachsel M Kaspar C Schliemann R Sommavilla JN Rybak, et al. 2008 A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int J Cancer 122 2405 2413 10.1002/ijc.23408 1:CAS:528:DC%2BD1cXltlaitbs%3D 18271006
8. K Zuberbühler A Palumbo C Bacci L Giovannoni R Sommavilla M Kaspar, et al. 2009 A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells Protein Eng Des Sel 22 169 174 10.1093/protein/gzn068 19022802
9. T Temma K Sano Y Kuge J Kamihashi N Takai Y Ogawa, et al. 2009 Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors Biol Pharm Bull 32 1272 1277 10.1248/bpb.32.1272 1:CAS:528:DC%2BD1MXhtVGhur7F 19571397
10. CM Overall C Lopez-Otin 2002 Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat Rev Cancer 2 657 672 10.1038/nrc884 1:CAS:528:DC%2BD38Xmslamsro%3D 12209155